Autres langues GeneTether Therapeutics Inc.

Actions

GTTX

CA37187D1087

Marché Fermé - Canadian Securities Exchange Autres places de cotation 21:19:38 24/06/2024			Varia. 5j.	Varia. 1 janv.
0,05 ^CAD	+150,00 %		+150,00 %	+25,00 %

30/05	GeneTether Therapeutics Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
29/03	GeneTether Therapeutics Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	30/05
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	30/03
GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
GeneTether Therapeutics Inc. Announces Fiscal Year 2023 Financial Results and Reports on Corporate Highlights	28/03
GeneTether Therapeutics Inc. Announces Third Quarter 2023 Financial Results	29/11
GeneTether Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	28/11
GeneTether Therapeutics Board Provides Shareholder Update	20/10/23
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2023.	30/09/23
GeneTether Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	26/08/23
GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/05/23
GeneTether Therapeutics Engages Gad Berdugo, Managing Partner of Explorium Capital LLC, as Advisor to Explore Strategic Alternatives for GeneTether Technology Platform	01/05/23
GeneTether Therapeutics Inc. Announces Fiscal Year 2022 Financial Results and Reports on Corporate Highlights	28/04/23
GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	28/04/23
GeneTether Therapeutics Inc. Update - From the Desk of the CEO	31/03/23
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2023.	30/03/23
GeneTether Therapeutics Inc. Announces Commencement of Strategic Review Process	09/02/23
GeneTether Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	25/11/22
GeneTether Therapeutics Inc. Announces Third Quarter 2022 Financial Results and Reports on Corporate Highlights	25/11/22
GeneTether Therapeutics Inc. Update - From the Desk of the CEO	25/10/22
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2022.	30/09/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues GeneTether Therapeutics Inc.

Actions

GTTX

CA37187D1087

Autres langues

Filtres